Fierce Pharma3h
Senators expand probe of Pfizer, Lilly DTC platforms to include telehealth provider partners
In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...
Healio3h
Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
Health on MSN8d
Zepbound Is Now Available in Additional Doses at Lower Costs
Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Indianapolis Business Journal7d
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...
New weight loss drugs aim to save muscle
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
The State of Weight Loss Drugs
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
The Victoria Advocate17d
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
Your healthcare provider is the best person to help you decide if Zepbound is right for you. Zepbound ® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and ...
Nasdaq17d
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
LillyDirect® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. * The in-person and telehealth providers listed on the LillyDirect site are ...